Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Keytruda (pembrolizumab) for the Treatment of Metastatic Melanoma

Drug Name (Brand / Generic)

Keytruda / pembrolizumab

Developed by

Merck (MSD)

Therapy Class

Anti-PD-1 (programmed death receptor-1) therapy

Product Description

Monoclonal antibody (mAb)

Current Indication

Metastatic melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, classical Hodgkin lymphoma, microsatellite instability-high (MSI-H) cancer, urothelial bladder cancer, gastric cancer, cervical cancer, primary mediastinal B-cell lymphoma, hepatocellular carcinoma, Merkel cell carcinoma

Market Sector

Oncology

Development Status

Approved in the US, Canada, Europe, Japan, China and Australia
Expand
Close
Close
Close

Go Top